Fundraising FoxApertor Pharmaceuticals
New York, US · Founded 2020
Find your way into Apertor Pharmaceuticals
Sign up to see every warm intro you have to Apertor Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Apertor Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Apertor develops a class of therapeutics called Interceptors that selectively disrupt disease-causing protein-protein interactions through proximity induction, recruiting an abundant protein found in cancer cells to block the interactions. The company uses a synthetic biology platform to build a pipeline of cancer treatments.
Founders & leadership
Board
PE
SH
Seth HarrisonBoard directorFounder and Managing Partner at Apple Tree Venture Management Llc
RT
Robert T. AbrahamBoard director
Reported raises · per SEC filings
Form D private placements$3M disclosed across 1 round · 2020
▶$3MraisedNov 2020 · 1 investors · PharmaceuticalsRule 506(b)
▶$3MraisedNov 2020 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Edmund GrazianiExecutive Officer, Director
- Robert T. AbrahamDirector
- Paul EisenbergDirector
- Seth HarrisonDirector
- Spiros LirasExecutive Officer, Director
- Offering amount
- $50M
- Amount sold
- $3M
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Apertor Pharmaceuticals do?
- Apertor develops a class of therapeutics called Interceptors that selectively disrupt disease-causing protein-protein interactions through proximity induction, recruiting an abundant protein found in cancer cells to block the interactions. The company uses a synthetic biology platform to build a pipeline of cancer treatments.
- How much funding has Apertor Pharmaceuticals raised?
- Apertor Pharmaceuticals has disclosed $3M raised across 1 round.
- Where is Apertor Pharmaceuticals headquartered?
- Apertor Pharmaceuticals is headquartered in New York, US.